Potent antibacterial agent which disrupts lipid bilayer synthesis through inhibition of LpxC (IC50
= 1.1 nM in Pseudomonas aeruginosa
); effective against a range of gram negative bacteria.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
Montgomery et al.